相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Olaparib monotherapy as primary treatment in unselected triple negative breast cancer
H. P. Eikesdal et al.
ANNALS OF ONCOLOGY (2021)
Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer
Jeffrey A. How et al.
CANCERS (2021)
Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma
Hisamitsu Takaya et al.
SCIENTIFIC REPORTS (2020)
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
R. E. Miller et al.
ANNALS OF ONCOLOGY (2020)
The RECAP Test Rapidly and Reliably Identifies Homologous Recombination-Deficient Ovarian Carcinomas
Lise M. van Wijk et al.
CANCERS (2020)
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
A. Gonzalez-Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
R. L. Coleman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas
Marthe M. de Jonge et al.
CLINICAL CANCER RESEARCH (2019)
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
I. Ray-Coquard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
C. Cruz et al.
ANNALS OF ONCOLOGY (2018)
A Functional Homologous Recombination Assay Predicts Primary Chemotherapy Response and Long-Term Survival in Ovarian Cancer Patients
Manuela Tumiati et al.
CLINICAL CANCER RESEARCH (2018)
Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
Darren R. Hodgson et al.
BRITISH JOURNAL OF CANCER (2018)
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
Marta Castroviejo-Bermejo et al.
EMBO MOLECULAR MEDICINE (2018)
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
K. Moore et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Functional Ex Vivo Assay Reveals Homologous Recombination Deficiency in Breast Cancer Beyond BRCA Gene Defects
Titia G. Meijer et al.
CLINICAL CANCER RESEARCH (2018)
Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer
Adriaan Vanderstichele et al.
EUROPEAN JOURNAL OF CANCER (2017)
Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer
Elizabeth L. Christie et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman et al.
LANCET (2017)
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Eric Pujade-Lauraine et al.
LANCET ONCOLOGY (2017)
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
Helen Davies et al.
NATURE MEDICINE (2017)
Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer
Britta Weigelt et al.
CLINICAL CANCER RESEARCH (2017)
Trabectedin as a chemotherapy option for patients with BRCA deficiency
Bradley J. Monk et al.
CANCER TREATMENT REVIEWS (2016)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
M. R. Mirza et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Panagiotis A. Konstantinopoulos et al.
CANCER DISCOVERY (2015)
Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs
Andrea M. Marquard et al.
BIOMARKER RESEARCH (2015)
Assessing the function of homologous recombination DNA repair in malignant pleural effusion (MPE) samples
M. J. Patterson et al.
BRITISH JOURNAL OF CANCER (2014)
Functional Ex Vivo Assay to Select Homologous Recombination-Deficient Breast Tumors for PARP Inhibitor Treatment
Kishan A. T. Naipal et al.
CLINICAL CANCER RESEARCH (2014)
An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer
Monjri M. Shah et al.
GYNECOLOGIC ONCOLOGY (2014)
Clinical Evaluation of a Multiple-Gene Sequencing Panel for Hereditary Cancer Risk Assessment
Allison W. Kurian et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Integrated analysis of germline and somatic variants in ovarian cancer
Krishna L. Kanchi et al.
NATURE COMMUNICATIONS (2014)
Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers
Johnathan A. Watkins et al.
BREAST CANCER RESEARCH (2014)
Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy
Marieke A. Vollebergh et al.
BREAST CANCER RESEARCH (2014)
Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes
Kirsten M. Timms et al.
BREAST CANCER RESEARCH (2014)
Tumor Mutation Burden Forecasts Outcome in Ovarian Cancer with BRCA1 or BRCA2 Mutations
Nicolai Juul Birkbak et al.
PLOS ONE (2013)
Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer
V. Abkevich et al.
BRITISH JOURNAL OF CANCER (2012)
Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 Inactivation
Tatiana Popova et al.
CANCER RESEARCH (2012)
Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas
Barbara Norquist et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing
Tom Walsh et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks
Samuel F. Bunting et al.
CELL (2010)
A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer
Monika Graeser et al.
CLINICAL CANCER RESEARCH (2010)
Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors
Asima Mukhopadhyay et al.
CLINICAL CANCER RESEARCH (2010)
53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers
Peter Bouwman et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2010)
Utility of DNA Repair Protein Foci for the Detection of Putative BRCA1 Pathway Defects in Breast Cancer Biopsies
Henning Willers et al.
MOLECULAR CANCER RESEARCH (2009)
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
Wataru Sakai et al.
NATURE (2008)
分享论文
